Reductions in insulin sensitivity occur during normal pubertal development and are known to be greater in those with Type I (insulin dependent) diabetes mellitus [1, 2] . These changes have been attributed to alterations in insulin action in peripheral tissues [3] , and are thought to occur secondary to puberty-associated increases in growth hormone (GH) secretion [4] which are exaggerated in Type I diabetes [5] . Nevertheless, the mechanisms that regulate insulin sensitivity are not clearly defined and could involve factors that alter insulin action at the level of the insulin receptor, as well as changes in post receptor signalling events.
] using an overnight (1800±0800 hours) variable rate insulin infusion euglycaemic clamp protocol (5 mmol/l). Plasma free insulin concentrations during steady-state euglycaemia were used as an index of insulin sensitivity and insulin clearance determined as a ratio of insulin infusion rate to plasma free insulin. Results. During steady-state euglycaemia (0500± 0730 hours), insulin sensitivity [mean (SEM) plasma insulin 0.020 (0.002) mU/l] and insulin clearance rates [19.1 (1.8) ml × kg ±1 × min] varied with age non-linearly and in a reciprocal fashion to each other (cubic regression F = 4.09, p = 0.01; F = 3.55, p = 0.02, respectively). Insulin sensitivity was negatively related to BMI (r = ±0.37, p = 0.011) and mean overnight growth hormone concentrations (r = ±0.40, p = 0.007). Insulin clearance was only related to growth hormone concentrations (r = ±0.37, p = 0.014). These relations were still evident after stepwise multiple regression analysis (potential determinants: C peptide, sex, age, puberty stage, HbA 1 c , duration of diabetes): insulin sensitivity r = 0.55, p < 0.001; insulin clearance r = 0.37, p < 0.02. Conclusions/interpretation. Insulin clearance rates vary with age in young subjects with Type I diabetes and are highest during mid-adolescence when insulin sensitivity is at its lowest. Both insulin sensitivity and insulin clearance are related to circulating growth hormone concentrations. [Diabetologia (2000) 43: 61±68] Keywords Type I diabetes, insulin sensitivity, insulin clearance, growth hormone, age, body mass index, children and adolescents. gree of obesity [11] and circulating GH concentrations [12] . Furthermore, in adolescents with Type I diabetes changes in insulin clearance rates during the night have been implicated in the aetiology of the dawn phenomenon [13, 14] Insulin clearance rates during puberty and early adult life have not been defined in patients with Type I diabetes. The aims of our study were to determine insulin clearance rates in a large cohort of children and adolescents with Type I diabetes using euglycaemic clamp techniques to establish relations with measures of insulin sensitivity and with factors such as obesity, puberty stage and GH secretion.
Subjects and methods
Subjects. Children and young adults (n = 46, 15 males) with Type I diabetes took part in the study. All were in good health with normal renal, hepatic and thyroid function and were on combinations of intermediate (isophane) and short acting (soluble) insulin given two to four times a day. Haemaglobin A 1 c and C-peptide concentrations (when blood glucose concentrations were greater than 7.0 mmol/l) were determined at the time of recruitment to the study. Patient characteristics are summarised in Table 1 . The Central Oxford Research Ethics Committee approved the study protocol and informed consent was obtained from subjects and, where appropriate, from their parents. All studies were carried out at the John Radcliffe Hospital in Oxford.
Research design. Before each study all intermediate insulin was withdrawn for at least 36 h. Blood glucose concentrations were controlled by four daily injections of soluble insulin; the last being given between 1200 and 1300 hours on the day of the study. Subjects were admitted to the ward at 1700 hours and two intravenous cannulae inserted, one into a distal forearm vein for blood sampling and the other into an antecubital fossa vein for infiltrating fluids. A standardised carbohydrate meal was given between 1730 and 1800 hours, and subjects then fasted until at least 0800 hours the next day. Baseline blood samples were taken at 1730 hours before commencing a variable rate insulin infusion that was given continuously overnight until 0800 hours the next morning. The rate of insulin infusion was adjusted according to 15 min blood glucose measurements to achieve and maintain a blood glucose concentration of around 5 mmol/l [15] . No glucose was given during this period.
Throughout the entire study period (1730 to 0800 hours) blood samples were taken at regular intervals for the measurement of GH (15 min) and plasma free insulin (30 min). Blood non-esterified fatty acids (NEFAs) were measured during the period of steady-state euglycaemia (15 min). Blood samples were taken from a continuously heparinised cannula inserted into a distal forearm vein, which was covered in a heated blanket to arterialise venous blood [16] . Blood sample volumes varied between 0.1±5.0 ml, depending on requirements and approximately 225 mls of blood were obtained from each subject during each study, which was replaced with an equivalent volume of normal saline. Subjects remained supine throughout and had similar sleep patterns.
Assay methods. Free insulin concentrations were determined by first mixing 1.0 ml of whole blood into a 25 % solution of polyethylene glycol 6000 (Merck, Poole, Dorset, UK) to remove insulin antibodies [17] . This was then centrifuged at 3000 rev/min in a Beckman Model J-6B Centrifuge and the supernatant separated and stored at ±20°C until assayed with a double antibody radioimmunoassay (Diagnostic Systems Laboratories, Webster, Texas, USA.). The intra-assay coefficients of variations were 8.2 %, 4.8 % and 6.3 % at 29, 106 and 328 pmol/l, respectively. The inter-assay coefficients of variation were 11.2 %, 9.2 % and 4.7 % at 30, 97 and 318 pmol/l, respectively.
Samples for GH analysis were initially kept at room temperature until completion of each study, before being spun and separated for storage at ±20°C. Plasma GH was then measured by immunoradiometeric assay (NETRIA, St. Bartholomew's Hospital, London, UK) using an international reference standard 80/505. All samples from each subject were analysed in the same batch. The intra-assay coefficients of variation at growth hormone concentrations of 2.9, 14.3 and 69.4 mU/l were 8.0, 2.0 and 3.4 %, respectively, while inter-assay coefficients of variation at GH concentrations of 3.5, 15.2 and 77.4 mU/l were 9.4, 7.7 and 10.5 % respectively. Assay sensitivity was quoted at 0.2 mU/l.
Plasma samples for NEFAs were stored at ±20°C until assay with a Wako NEFA C kit (Alpha Laboratories, Eastleigh, Hants, UK). The assay detection limit was 10 mmol/l and inter-assay and intra-assay coefficients of variation were 2.5 % at 500 and 1000 mmol/l.
Glycated haemoglobin levels (HbA 1 c ) were measured by high pressure liquid chromatography (HPLC) (Diamat, BioRad Laboratories, Hemel Hempstead, UK). The intra-assay coefficients of variation were 1.9 and 2.2 % at HbA 1 c values of 6.9 and 11.5 %, respectively. The inter-assay coefficients of variation were 2.7 and 2.3 % at HbA 1c values of 7.0 and 11.6 %, respectively. Normal range HbA 1 c values were 4.3 to 6.1 %. Concentrations of C peptide were determined by a double antibody radioimmunoassay (Diagnostic Products, Euro/ DPC, Llanberis, Caernarfon, Wales). Intra-assay coefficients of variation were 3.4 and 3.0 % at C peptide concentrations of 294 and 2614 pmol/l, respectively and inter-assay coefficients of variation were 10.0 and 1.9 % at C peptide concentrations of 297 and 2929 pmol/l, respectively. Whole blood glucose was measured at the bedside using a glucose oxidase method (YSI analyser, Clandon Scientific, Farnbourgh, Hants, UK). Data analysis. A period of steady-state euglycaemia was deemed to be achieved when blood glucose concentrations showed no statistically significant change with time within and between subjects as determined by analysis of variance (ANO-VA) for repeated measures. As a group this was achieved between 0500 and 0730 hours. Plasma free insulin concentrations for the period of steadystate euglycaemia were used as an index of insulin sensitivity. Changes in insulin concentrations required to maintain euglycaemia during this fasting period in subjects with Type I diabetes have been shown to be partly related to changes in peripheral insulin-stimulated glucose metabolism [18±20].
Metabolic clearance rates for plasma insulin (MCR-I) were determined for the period of steady-state euglycaemia as a ratio of insulin infusion rate to plasma free insulin concentration [21]:
Statistics. All data are expressed as means ± standard error of the mean (SEM) unless otherwise stated. Analysis of variance with repeated measures was used to determine the period of steady-state euglycaemia. The t test for independent samples was used to detect differences in mean data between the sexes. Cubic regression modelling was used to examine the non-linear relation between the dependent variables, insulin sensitivity and MCR-I, and age. Simple linear regression was used in comparisons with all other independent variables. The determinants of insulin sensitivity (as reflected by plasma free insulin concentrations) and of MCR-I were examined using stepwise (forwards) multiple regression analysis. We used SPSS for MS Windows 95 (release 7.5.1 (SPSS, Chicago, Ill., USA) for all analyses. P values less than 0.05 were considered to be significant.
Results
Overnight blood glucose concentrations declined steadily and concentrations approaching 5 mmol/l were achieved in most subjects by 0100 hours. During steady-state euglycaemia (0500 ± 0730 hours), mean blood glucose concentrations for the group were 5.5 ± 0.1 mmol/l, with no significant differences between the sexes (males = 5.3 ± 0.1 mmol/l vs females = 5.7 ± 0.2 mmol/l) (Fig. 1) .
Plasma free insulin concentrations during steadystate euglycaemia were 0.020 ± 0.002 mU/ml. No significant differences in free insulin concentrations for this period were observed when compared by sex (males = 0.018 ± 0.003 mU/ml vs females = 0.021 ± 0.002 mU/ml). A non-linear relation between plasma free insulin concentrations and age was seen, with those for steady-state euglycaemia at their lowest in the younger children and in the young adults, compared with young people in the mid-teenage years (Fig. 2 a) . This relation was statistically significant when examined by non-linear cubic regression modelling (F = 4.09, p = 0.01).
Mean insulin infusion rates and calculated mean MCR-Is during steady-state euglycaemia were 0.29 ± 0.02 units × kg ±1 × min ±1 and 19.1 ± 1.8 ml × kg ±1 × min ±1 , respectively. The MCR-Is were similar in male (18.7 ± 2.5 ml × kg ±1 × min
±1
) and female subjects (19.3 ± 2.4 ml × kg ±1 × min ±1
). There was a significant non-linear relation between MCR-Is and age, although this was the reciprocal of that seen between plasma free insulin and age (cubic regression F = 3.55, p = 0.02) (Fig. 2 b) . Predictably MCR-I's for steady-state euglycaemia were significantly correlated to plasma free insulin concentrations (r = 0.65, p = < 0.001).
Mean plasma GH concentrations for the overnight period between 2000 to 0800 hours were determined for each subject and ranged from a maximum value of 59.9 mU/l to a minimum of 6.2 mU/l (mean 21.8 ± 1.7 mU/l). No differences in mean values were seen between male (22.4 ± 3.8 mU/l) and female subjects (21.5 ± 1.9 mU/l). Mean plasma NEFAs during steady-state euglycaemia ranged from 347 mmol/l to 1467 mmol/l (mean 808 ± 53 mmol/l) with no differences seen between the sexes (mean males 766 ± 92 mmol/l vs females 830 ± 65 mmol/l). represents blood glucose clamp target. The period of steady-state euglycaemia between 0500 to 0730 hours is shown Insulin sensitivity, as determined by steady-state euglycaemia mean plasma free insulin concentrations, showed a significant linear relation to BMI (r = ±0.37, p = 0.011, Fig. 3 ), mean overnight GH concentrations (r = ±0.40, p = 0.007, Fig. 4 a) and puberty stage (p = 0.004). In contrast, MCR-Is were only reciprocally related to overnight GH (r = ±0.37, p = 0.014, Fig. 4 b) . These relations, with the exception of that between insulin sensitivity and puberty stage, were still evident when examined by stepwise (forward) multiple regression, in which all other variables thought to be potential determinants (including NEFAs, C peptide, sex, HbA 1 c and duration of diabetes) were entered into the model. The results of stepwise linear multiple regression analysis are shown in Table 2 .
Discussion
We used plasma free insulin concentrations during a period of steady-state euglycaemia as an index of peripheral insulin sensitivity. An association between changes in plasma insulin concentrations and insulin infusion requirements during the early morning period have been attributed to changes in insulin sensitivity and specifically to changes in insulin stimulated glucose metabolism in subjects with Type I diabetes [19, 20, 22] . We observed differences in insulin sensitivity according to age, with values at their lowest during the adolescent years (Fig. 2 a) . This is in keeping with previous reports that have noted reductions in insulin sensitivity coinciding with puberty in subjects with Type I diabetes [1, 2] . Variations were also seen with age, with MCR-Is falling and reaching a nadir in the mid-teenage years, before rising again in later life (Fig. 2 b) . We have shown a relation between insulin clearance and age in a large cohort of children and adolescents with Type I diabetes. In adults with diabetes this relation has not been previously reported, although in healthy adults MCR-I has been variously observed as remaining unchanged [23] or declining [9, 10] with advancing age. In these studies other age-related variables such as changes in physical activity and in metabolic rate could, however, have had a role in determining insulin clearance rates [24] .
We determined insulin clearance rates in subjects with Type I diabetes using a simple physiological model, using a variable rate insulin infusion, euglycaemic clamp technique. By maintaining normoglycaemia we have eliminated possible changes in insulin clearance induced by either hyperglycaemia or hypoglycaemia [21] . Also, by infusing physiological amounts of insulin, reductions in insulin clearance brought about by insulin receptor saturation and down-regulation, as encountered with supraphysiological insulin treatment, were also avoided [25] .
A positive relation between our measure of peripheral insulin sensitivity and overnight GH concentrations was observed. Similar findings have been reported in subjects with Type I diabetes, where measures of early morning insulin sensitivity were strongly related to overnight GH secretion [19, 26, 27, 28] . It is has been suggested that reductions in insulin sensitivity at this time are attributable to the effects of GH on peripheral glucose metabolism [3] . The insulin antagonistic effects induced by GH are thought to be principally mediated in the peripheral tissues [29, 30] yet the mechanisms for this effect are still ill defined. Growth hormone could be acting directly through its own receptor with interaction with insulin signalling at a post receptor level, or be acting indirectly through mobilisation of NEFAs from adipose tissue. These have suppressive effects on peripheral glucose metabolism by inhibiting peripheral glucose oxidation and glycolysis [31, 32, 33] and have been implicated in regulating hepatic glucose metabolism and mediating the actions of insulin on the liver [34, 35] .
We also observed a statistically significant negative linear relation between mean overnight GH concentrations and insulin clearance rates in keeping with other reports. In dogs, exogenous GH treatment results in reductions in insulin clearance [36] and in Turner's syndrome raised insulin clearance rates were decreased to normal with GH therapy [37] . Nevertheless, our results contrast with those seen in studies of the dawn phenomenon in patients with Type I diabetes, where raised early morning insulin requirements have been linked to increases in insulin clearance. This has been attributed to surges in noc- turnal GH secretion [13, 14] , although this has not been consistently observed [27, 38] . Methodological differences could account for the discrepancies seen between these and our studies, particularly as many used fixed insulin rates and the use of closed-loop insulin infusion devices (ªBiostator deviceº) which can introduce error in the calculation of insulin clearance rates [39, 40] . Moreover other factors, such as differences in the age of the subjects used and the presence of higher circulating insulin antibody titres can also affect insulin clearance [41] . Insulin antibodies were not measured in our study but are unlikely to have been present in our subjects given their young age and likelihood that all had been treated with recombinant human insulin since diagnosis. A relation between BMI and insulin clearance rates has also been reported [42] but was not seen in our study. This could be explained by the lack of any extremes in BMI values in our subjects, although a recent study of patients with polycystic ovarian syndrome noted that insulin clearance rates were reduced independent of BMI [43] .
Non-esterified fatty acids could be important in explaining the relations seen between insulin sensitivity and insulin clearance with both GH and BMI. A negative relation between BMI and insulin sensitivity is recognised in obese subjects with and without diabetes [44, 45, 46] , and there is evidence linking increased concentrations of NEFAs to the development of insulin resistance in subjects with increased BMI [47, 48] . Small increments in BMI have also been associated with reduced insulin clearance rates and increased NEFAs in patients with glucose intolerance [42] . Experiments in rats suggests that NEFAs reduce hepatic insulin uptake and insulin degradation [49, 50] . Furthermore, in humans NEFA's have been shown to alter hepatic insulin clearance and have been implicated in the reduced insulin sensitivity associated with Type II (non-insulin dependent) diabetes mellitus [51] . We did not see any relation between mean steady-state euglycaemia plasma NEFA concentrations with GH, insulin sensitivity or insulin clearance, although it cannot be entirely discounted. Early morning fasting ketone and NEFA concentrations seem to be determined by plasma insulin concentrations, whereas those during the early part of the night are related to GH [52] . The concentrations of NEFA in our study were measured from plasma samples that were collected and stored in the presence of heparin, which is well known to cause the release of NEFAs in blood through the activation of lipoprotein lipase activity and could have interfered with our final results [53] .
The relations seen in our study also raise the question as to whether insulin clearance could be another factor that regulates insulin sensitivity in patients with Type I diabetes. In vitro, after insulin receptor binding and internalisation into cells, insulin and the enzymatic processes involved in its degradation can have effects on the generation of insulin action [54, 55] . The liver is the primary site for the clearance of insulin from the circulation [56, 57] and in liver disease states, decreases in insulin clearance have been associated with reductions in hepatic insulin sensitivity [58] . In both non-diabetic insulin resistant patients and healthy human subjects strong relations between insulin sensitivity and insulin clearance have also been reported [59, 60] . Although it cannot be discounted that insulin clearance could be a determinant of insulin sensitivity there are other explanations that could account for this association. For example, reductions in insulin receptor numbers at the tissues would have an affect on both insulin clearance rates and insulin action. There is some evidence that factors causing abnormalities in the post-receptor mechanisms that could be responsible for reduced insulin sensitivity could also cause reductions in insulin receptor numbers and thus reduce insulin receptor mediated clearance [61] .
In conclusion, our study has shown that insulin clearance rates vary with age in young subjects with Type I diabetes and are highest during mid-adolescence when insulin sensitivity is at its lowest. Both insulin clearance and insulin sensitivity are related to circulating GH concentrations, whereas insulin sensitivity alone is correlated with BMI values. Our study highlights the complex inter-relations that exist between age, GH and BMI in the determination of insulin sensitivity in subjects with Type I diabetes. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic distrubances of diabetes mellitus. 
